Yu Bai

Mr. Yu Bai


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
ZZZhichao Zhu
Zhichao Zhu
LHLiuyang He
Liuyang He
YBYu Bai
Yu Bai
LXLei Xia
Lei Xia
XSXiao Sun
Xiao Sun
CQChunjian Qi
Chunjian Qi
As the largest proportion of myeloid immune cells in tumors, macrophages play an important role in tumor growth and regression according to their different phenotypes, thus reprogramming macrophages has become a new research direction for cancer immunotherapy. Yeast-derived whole β-glucan particles (WGPs) can induce M0 macrophages to differentiate into M1 macrophages and convert M2 macrophages and tumor-associated macrophages (TAMs) into M1 macrophages. In vitro, studies have confirmed that WGP-treated macrophages increase the activating receptors in natural killer cells (NK cells) and enhance the cytotoxicity of NK cells. The extracellular regulated protein kinases (ERK) signaling pathway is involved in WGP-mediated regulation of the macrophage phenotype. Further in vivo studies show that oral WGP can significantly delay tumor growth, which is related to the increased proportion of macrophages and NK cells, the macrophage phenotype reversal, and the enhancement of NK cell immune function. NK-cell depletion reduces the therapeutic efficacy of WGP in tumor-bearing mice. These findings revealed that in addition to T cells, NK cells also participate in the antitumor process of WGP. It was confirmed that WGP regulates the macrophage phenotype to regulate NK-cell function.

18 February 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
DLDefeng Li
Defeng Li
MYMei-Feng Yang
Mei-Feng Yang
XCxin chang
xin chang
NWNannan Wang
Nannan Wang
FTFang-Fang Tan
Fang-Fang Tan
YBYu Bai
Yu Bai

11 October 2025 in Endocrine
Verified
Journal Article
Closed access
PDF file
YBYu Bai
Yu Bai
YYYue Yin
Yue Yin
YJYuanyuan Jiao
Yuanyuan Jiao
YZYanhua Zhang
Yanhua Zhang
HLHong Liu
Hong Liu

10 November 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
YBYu Bai
Yu Bai
YYYue Yin
Yue Yin
HLHong Liu
Hong Liu
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy. However, these therapies commonly precipitate immune-related adverse events, with thyroid dysfunction being the most frequent manifestation of endocrine toxicity. Whether subclinical abnormal baseline thyroid function (sABTF) predisposes to overt thyroid dysfunction during ICI therapy—and if so, how it influences time-to-onset, phenotype, severity, and clinical decision have not been fully elucidated. Methods: We conducted a retrospective cohort study of 235 patients with cancer who underwent ICI therapy at Peking University Cancer Hospital between January 1, 2018, and September 30, 2024. Patients were stratified by baseline thyroid function status and monitored for ICI-induced overt thyroid dysfunction. Multivariate logistic regression analysis identified the risk factors for overt thyroid dysfunction. To examine baseline free thyroxine (FT4) cutoff, we used restricted cubic splines and receiver operating characteristic (ROC) analysis. Time-to-event was estimated using Kaplan-Meier curves and multivariate Cox models. Results: Among 99 patients with sABTF, 51.52% developed overt thyroid dysfunction during ICI therapy. Baseline FT4 was associated with overt hypothyroidism (adjusted odds ratio [OR], 0.88; 95% confidence interval [CI], 0.78–0.99; p = 0.037). A data-driven FT4 threshold of 13.91 pmol/L showed moderate discrimination (area under the ROC curve, 0.687). Using this threshold, higher FT4 (≥13.91 pmol/L) was associated with substantially lower odds of overt hypothyroidism (adjusted OR, 0.17; 95% CI, 0.06–0.47; p = 0.001), indicating that patients with FT4 <13.91 pmol/L were at markedly elevated risk. Severe subclinical hypothyroidism at baseline (TSH ≥10 mIU/L) was associated with a shorter time to overt hypothyroidism (median 7.78 weeks; adjusted hazard ratio [HR], 2.84; 95% CI, 1.42–5.67; p = 0.003), with the highest risk observed among patients who also had FT4 <13.91 pmol/L (median 6.57 weeks; adjusted HR, 10.05; 95% CI, 3.13–32.23; p < 0.001). Conclusions: Pre-existing thyroid abnormalities, particularly severe subclinical hypothyroidism with concurrent FT4 <13.91 pmol/L, identify a high-risk subgroup prone to an earlier onset of ICI-induced overt hypothyroidism. These data support comprehensive baseline assessments and intensified early monitoring to enable timely detection and management during ICI therapy.

28 October 2024 in Discover Medicine
Verified
Journal Article
Open access
PDF file
YBYu Bai
Yu Bai
DJDan Jiang
Dan Jiang
YWYong-Qing Wen
Yong-Qing Wen
WWWen-Juan Wang
Wen-Juan Wang
ZSZai-Wei Song
Zai-Wei Song
Objective This study was conducted to delineate the correlation between polymorphisms in methylenetetrahydrofolate reductase (MTHFR) and toxicity of 5-fluorouracil (5-FU)-based chemotherapy regimens in the Asian demographic. Methods A systematic review across PubMed, Embase, and the Cochrane Library databases from inception up to November 23, 2023, was performed. We employed standardized methods for data extraction and quality evaluation, followed by a meta-analysis to ascertain odds ratios and 95% confidence intervals associated with chemotherapy-induced toxicity. Results This systematic review and meta-analysis integrated results from nine studies, encompassing a total of 1882 patients with cancer. Notably, there was a pronounced increase in the risk of severe haematological toxicity (notably neutropenia) and gastrointestinal toxicity (specifically diarrhea) among patients harbouring the MTHFR 677 C>T variant. Conversely, the relationship between the MTHFR 1298 A>C polymorph and chemotherapy-induced toxicity remained ambiguous. The integrity of the results was confirmed through publication bias and sensitivity analyses, demonstrating the robustness and reliability of the findings. Conclusions A link exists between MTHFR 677 C>T and heightened toxicity risk in Asian patients undergoing 5-FU-based chemotherapy.

18 November 2023 in Nutrition and Cancer
Verified
Journal Article
Closed access
YBYu Bai
Yu Bai
YWYong-Qing Wen
Yong-Qing Wen
XMXu Ma
Xu Ma